Susan-Resiga Delia, Girard Emmanuelle, Kiss Robert Scott, Essalmani Rachid, Hamelin Josée, Asselin Marie-Claude, Awan Zuhier, Butkinaree Chutikarn, Fleury Alexandre, Soldera Armand, Dory Yves L, Baass Alexis, Seidah Nabil G
From the Laboratory of Biochemical Neuroendocrinology, Montreal, Quebec H2W 1R7, Canada.
the Department of Medicine, McGill University, Montreal, Quebec H3G 2M1, Canada.
J Biol Chem. 2017 Feb 3;292(5):1573-1590. doi: 10.1074/jbc.M116.769430. Epub 2016 Dec 20.
Familial hypercholesterolemia (FH) is characterized by severely elevated low density lipoprotein (LDL) cholesterol. Herein, we identified an FH patient presenting novel compound heterozygote mutations R410S and G592E of the LDL receptor (LDLR). The patient responded modestly to maximum rosuvastatin plus ezetimibe therapy, even in combination with a PCSK9 monoclonal antibody injection. Using cell biology and molecular dynamics simulations, we aimed to define the underlying mechanism(s) by which these LDLR mutations affect LDL metabolism and lead to hypercholesterolemia. Our data showed that the LDLR-G592E is a class 2b mutant, because it mostly failed to exit the endoplasmic reticulum and was degraded. Even though LDLR-R410S and LDLR-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR-WT. Evidence is provided for a tighter association of LDL with LDLR-R410S at acidic pH, a reduced LDL delivery to late endosomes/lysosomes, and an increased release in the medium of the bound/internalized LDL, as compared with LDLR-WT. These data suggested that LDLR-R410S recycles loaded with its LDL-cargo. Our findings demonstrate that LDLR-R410S represents an LDLR loss-of-function through a novel class 8 FH-causing mechanism, thereby rationalizing the observed phenotype.
家族性高胆固醇血症(FH)的特征是低密度脂蛋白(LDL)胆固醇严重升高。在此,我们鉴定出一名FH患者,其低密度脂蛋白受体(LDLR)存在新的复合杂合突变R410S和G592E。该患者对最大剂量瑞舒伐他汀加依折麦布治疗反应一般,即使联合注射PCSK9单克隆抗体也是如此。我们旨在通过细胞生物学和分子动力学模拟来确定这些LDLR突变影响LDL代谢并导致高胆固醇血症的潜在机制。我们的数据表明,LDLR-G592E是2b类突变体,因为它大多无法离开内质网并被降解。尽管LDLR-R410S和LDLR-WT在细胞表面水平和总受体水平上相似,并且与LDL或细胞外PCSK9的结合能力相同,但LDLR-R410S对内体/溶酶体中外源PCSK9介导的降解具有抗性,并且相对于LDLR-WT,其LDL内化和降解减少。与LDLR-WT相比,有证据表明在酸性pH下LDL与LDLR-R410S的结合更紧密,LDL向晚期内体/溶酶体的递送减少,以及结合/内化LDL在培养基中的释放增加。这些数据表明LDLR-R410S与其负载的LDL一起循环利用。我们的研究结果表明,LDLR-R410S通过一种新的8类FH致病机制代表LDLR功能丧失,从而解释了观察到的表型。